A2Z Cust2Mate Solutions Corp (AZ)

$AZ sold half about 44%

$AZ likely 10x https://x.com/rtelford_invest/status/1940108225011229021?s=48

$AZ I believe we are on the launch pad, $400 m market cap, tiny and has a huge market lease position in a bluesky market . 2 contracts already and I suspect many many more. Short term aim for year end is $2B or close to $50 pps .

$AZ looking ready for the next leg up on this slow day 📈 Follow to be in 1st 🥇 FREE HOT trade ideas daily 📟

$AZ stock price making the turn upwards 👀

40% $PCT / 40% $AZ / 10% $BTC.X / 10% $ETH.X

Keep $AZ on your radar, I think it is worth a starter here against distribution week under 10-week SMA

$AZ ✅ Technology - Small Cap - Momentum Trap F-Score: 3/9 🏦 Analysts: 1x buy rating 👨‍🔬 Potential: Trading at approximately 86% below estimate of its fair value 💠 Range (12m) $0.89 - $11.00 💰 RSI: 60.44 (bullish momentum) 📊 NEWSDESK (article idea is for AZ only) 📰 https://finance.yahoo.com/news/3-growth-stocks-high-insider-173533180.html

$AZ AstraZeneca reports Datroway approved in U.S. for EGFR-mutated NSCLC Datroway has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy, AstraZeneca announced. "This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The approval follows Priority Review and Breakthrough Therapy Designation by the Food and Drug Administration based on results from a subgroup analysis of the TROPION-Lung05 Phase II trial and supported by data from the TROPION-Lung01 Phase III trial," AstraZeneca stated.

I found you a MACD Bearish Reversal Divergence on the daily chart of A2Z Smart Technologies Corp. $AZ #BearishReversalDivergence #NASDAQ